Santhera (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the discovery, development and commercialization of innovative pharmaceutical products for the treatment of orphan neuromuscular diseases. The Company's vision is to become a leading specialist offering therapies for a number of indications in this area of high unmet medical need. Santhera's first product, Catena® has recently been shown to imporve the vision of patients with Leber's Hereditary Optic Neuropathy (LHON). The drug is also being clinically tested in Duchenne Muscular Dystrohphy, Primary progressive Multiple Sclerosis and MELAS Syndrome. A recent Phase IIb study showed that fipamezole, Santhera's second compound, reduces levodopa-induced Dyskinesia in Parkinson's Disease. Two other development programs encompass omigapil in Congenital Muscular Dystrophy and MC-4R antagonists in cancer cachexia (in late preclinical stage).
For further information, please visit the Company’s Web site www.santhera.com. Catena® is a trademark of Santhera Pharmaceuticals.